The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Alliance Working to Rein in Power of PBMs

Alliance Working to Rein in Power of PBMs

May 17, 2017 • By Kathy Holliman

  • Tweet
  • Email
Print-Friendly Version / Save PDF

A coalition of patient and provider groups, including the ACR, is raising awareness about the effect of pharmacy benefit managers (PBMs) on patient care and the cost of prescription drugs. The Alliance for Transparent and Affordable Prescriptions, or ATAP, argues that too few restrictions have been placed on PBM transparency, and requirements for PBMs to pass negotiated savings on to payers and patients are needed.

You Might Also Like
  • Express Scripts Tries to Rein in Pricey Inflammatory Drugs
  • Unwise Choices: EHRs, PBMs, Drug Costs Are Leading to Physician Burnout
  • 2017 Proves There’s ‘Power in Numbers’
Also By This Author
  • Wisconsin Rheumatologist Visits Rheumatology Training Program in Nepal

The ATAP Steering Committee includes representatives from the ACR, Arthritis Foundation, National Psoriasis Foundation, CSRO, National Organization of Rheumatology Managers, Rheumatology Nurses Society and Global Healthy Living Foundation.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Adam Cooper, MS, the ACR’s senior director of government affairs, says the coalition hopes to “educate policymakers about the problem and possible solutions.” These solutions, he says, could include “legislative and other fixes that would bring about greater transparency and accountability for PBMs.”

How PBMs Affect Patients & Costs
Eugene Huffstutter, MD, a rheumatologist in Hixson, Tenn., and the ACR’s representative to the Alliance, says patient care is negatively affected by PBMs because a formulary may prevent access to certain medications. “The PBM process can negatively affect patient care by preventing new and innovative products from getting to patients. Even if a drug has been shown to be superior—or even cheaper—the PBM system is going to make you use the [drugs] on the formulary.”

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Many physicians may not currently understand how the PBMs work and how they affect patient care, he says. “This is a rapidly moving field. Once people start understanding how much money is involved—[especially] in this era when we are all trying to watch costs—then there could be a lot of change. This affects not only private insurance, but also Medicare D plans.”

PBMs Left Unchecked
The Alliance contends the PBM industry is overly consolidated: Combined, the two largest PBMs cover more than 170 million Americans. This consolidation results in one-sided formulary negotiations with pharmaceutical manufacturers and a take-it-or-leave-it demand by the PBMs.

According to the Alliance, PBMs currently have no checks on conflicts of interest. Many PBMs own their own specialty or mail-order pharmacies and require beneficiaries to use their pharmacies. Not only does this reduce the ability to make choices, but a mail-order pharmacy eliminates the opportunity for a beneficiary to interact with a pharmacist. Further, drug discounts or rebates negotiated by PBMs often do not translate into cost savings for beneficiaries.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

“Patients often never see any savings on the cost of drugs, because it all goes back to the insurance companies or stays with the PBM,” Dr. Huffstutter says. “Transparency about the process is greatly needed so that we understand what is going on with drug prices. This kind of arrangement artificially inflates the costs of medications.”

Pages: 1 2 | Single Page

Filed Under: Legislation & Advocacy, Professional Topics Tagged With: drug costs, pharmacy benefit managers (PBMs), The Alliance for Transparent and Affordable Prescriptions

You Might Also Like:
  • Express Scripts Tries to Rein in Pricey Inflammatory Drugs
  • Unwise Choices: EHRs, PBMs, Drug Costs Are Leading to Physician Burnout
  • 2017 Proves There’s ‘Power in Numbers’
  • 5 Ways to Unlock the Power of Consultation

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)